rpe65c Antibody

What is RPE65 and why is it important in vision research?

RPE65 is a 65 kDa protein that functions as a critical isomerohydrolase in the retinoid cycle, playing an essential role in the regeneration of 11-cis-retinal, the chromophore necessary for rod and cone opsins . It catalyzes the cleavage and isomerization of all-trans-retinyl fatty acid esters to 11-cis-retinol, which is then oxidized by 11-cis retinol dehydrogenase to produce 11-cis-retinal for use as a visual chromophore . This protein is fundamental to vision research because it is essential for the production of 11-cis retinal for both rod and cone photoreceptors, making it a critical component in the visual cycle . Additionally, RPE65 has been found to catalyze the isomerization of lutein to meso-zeaxanthin, an eye-specific carotenoid, further expanding its significance in ocular physiology . Recent research has revealed unexpected localization of RPE65 within the outer segments of human green/red cones, suggesting additional roles beyond its well-established function in the retinal pigment epithelium (RPE) .

Which experimental models are suitable for RPE65 antibody research?

Several experimental models have proven suitable for RPE65 antibody research, with human, mouse, and rat samples being among the most validated targets . According to antibody validation studies, commercial RPE65 antibodies have demonstrated specificity in these species, making them reliable models for comparative studies . Human donor eyes from various age groups (ranging from 11 to 85 years old) have been successfully used for RPE65 immunolocalization studies, allowing for age-related analysis of expression patterns . For cellular models, both primary retinal pigment epithelium cultures and certain transfected cell lines (such as COS7 cells transfected with human RPE65) have been employed effectively . When selecting an experimental model, it's essential to consider the specific antibody being used, as some have been more extensively validated in certain species than others, and to include appropriate controls to confirm specificity in your chosen model system .

What are the common applications for RPE65 antibodies in research?

RPE65 antibodies are utilized across multiple research applications with varying protocols and optimization requirements. Western blotting (WB) is commonly employed to detect RPE65 protein (~65 kDa band) in tissue lysates, with recommended dilutions typically ranging from 1-2 μg/ml to 0.2 μg/ml depending on the specific antibody . Immunohistochemistry (IHC) applications include both paraffin-embedded and frozen section protocols, with optimal antibody dilutions around 1:250-1:500 . Immunocytochemistry and immunofluorescence techniques are also widely used, particularly for cellular localization studies, with recommended dilutions of approximately 1:50-1:200 . Some RPE65 antibodies have been validated for immunoprecipitation studies and in vivo assays as reported in scientific literature . For dual-labeling studies, RPE65 antibodies have been successfully paired with markers for photoreceptors (rhodopsin, cone arrestin) and glial cells (glutamine synthetase) to determine cellular localization patterns . The versatility of these applications facilitates comprehensive investigation of RPE65 expression, localization, and function in visual cycle research.

How do I validate specificity of RPE65 antibodies?

Table 1: RPE65 antibody epitope details and cross-species conservation. B: Bovine; M: mouse; H: human.

How can I optimize RPE65 antibody use for different tissue preparation techniques?

Optimizing RPE65 antibody protocols for different tissue preparation techniques requires specific adaptations to maximize signal while minimizing artifacts. For paraffin-embedded tissues, antigen retrieval methods are critical and have been successfully implemented using heat-induced antigen retrieval (HIER) with 10mM sodium citrate buffer (pH 6.0) for 20 minutes, followed by endogenous peroxidase quenching using peroxide block . Primary antibody incubation periods of 30 minutes have been effective in automated systems like the Bond Rx autostainer, though manual protocols may require longer incubation times . For frozen sections, fixation parameters must be carefully controlled as overfixation can mask RPE65 epitopes; published protocols have successfully used these preparations with antibody dilutions around 1:250 . Fresh tissue preparations require rapid processing to prevent protein degradation, while dissected RPE samples have been successfully homogenized for immunoblotting with antibody concentrations of 0.2 μg/ml . When working with cultured cells, it's important to note that RPE65 expression may decrease over time in culture; research has shown that in cultured bovine RPE cells, RPE65 protein becomes undetectable by western blot after day 14, despite persistent mRNA expression for at least 7 weeks . For each preparation technique, optimization should include dilution series tests and appropriate positive controls where RPE65 expression is well-established.

What are the considerations for RPE65 antibody selection for dual immunostaining experiments?

Dual immunostaining experiments with RPE65 antibodies require careful consideration of several technical parameters to ensure reliable results. First, the host species of each primary antibody must be different to avoid cross-reactivity of secondary antibodies; current commercial RPE65 antibodies are predominantly rabbit-derived, so paired antibodies should come from different species (mouse, goat, etc.) . Second, epitope compatibility must be assessed—RPE65 antibodies targeting distinct epitopes (such as PETLET targeting residues 150-164 versus DALEED targeting residues 473-486) have been successfully used in sequential staining protocols . Third, the fluorophore emission spectra must be sufficiently separated to prevent bleed-through during imaging; successful dual immunofluorescence has been achieved when pairing RPE65 detection with markers such as cone arrestin or glutamine synthetase . Fixation protocols require optimization as different antibody combinations may have different sensitivities to fixatives; published protocols have successfully used frozen sections of human retina for dual labeling . Blocking steps must be rigorously performed to prevent non-specific binding, particularly when using multiple antibodies from similar host species. Sequential staining approaches (complete staining with first antibody before introducing the second) may be necessary when using antibodies with cross-reactive potential. Validation of dual staining patterns should include single-antibody controls to confirm that the presence of one antibody doesn't alter the staining pattern of the other.

What methodological adaptations are needed for detecting RPE65 in cone photoreceptors?

Detecting RPE65 in cone photoreceptors requires specialized methodological adaptations due to its unexpected localization pattern and potentially lower expression levels compared to RPE. First, antibody selection is critical—antibodies must be validated specifically for cone detection, as demonstrated in studies using two different polyclonal antibodies (PETLET and DALEED) targeting distinct RPE65 epitopes, which both confirmed cone localization . Tissue preparation techniques must be optimized, with frozen sections generally yielding better results than paraffin-embedded tissues for detecting RPE65 in cones . Co-staining strategies are essential for definitive identification; successful approaches have paired RPE65 antibodies with cone-specific markers like cone arrestin to conclusively identify cone photoreceptors expressing RPE65 . Imaging parameters require adjustment, including increased exposure times or amplification steps that may be necessary to detect potentially lower RPE65 signals in cones compared to RPE . Controls must include both positive controls (RPE tissue) and negative controls (rhodopsin-positive rods or glutamine synthetase-positive Müller glia), which have been shown not to express RPE65 . Species-specific considerations are important, as localization patterns may vary; current evidence shows RPE65 specifically in human green/red cones, but this pattern should not be assumed across all species without verification . Post-acquisition analysis might require deconvolution or other image processing techniques to clearly distinguish the subcellular localization, which has been specifically identified in the outer segments of cones .

How should RPE65 antibody dilutions be optimized for different experimental applications?

Optimizing RPE65 antibody dilutions for different experimental applications requires systematic testing based on established starting points from literature and manufacturer recommendations. For western blotting, published protocols have successfully used concentrations ranging from 0.2 μg/ml to 2 μg/ml, with lower concentrations (0.2 μg/ml) often sufficient for detecting the 63-65 kDa RPE65 band in RPE homogenates . Immunohistochemistry applications typically require higher antibody concentrations, with successful results reported at dilutions of 1:250-1:500 for paraffin sections and approximately 2 μg/ml for frozen sections . Immunocytochemistry and immunofluorescence applications generally require higher antibody concentrations than western blotting, with effective dilutions ranging from 1:50 to 1:200 . For each application, a dilution series test should be performed using positive control samples with known RPE65 expression (such as RPE tissue); this should include at least three dilutions spanning the recommended range to identify optimal signal-to-noise ratios . The optimization process should include appropriate negative controls (secondary antibody only, tissues not expressing RPE65) at each dilution to assess non-specific binding . Batch variation should be considered, as different lots of the same antibody may require slightly different working dilutions; recombinant monoclonal antibodies like EPR22579-44 offer advantages for batch-to-batch consistency . Optimization should also consider sample-specific factors such as fixation method, antigen retrieval protocol, and detection system (fluorescent vs. enzymatic) .

Why might RPE65 antibody show variable immunostaining in different retinal regions?

Variable RPE65 immunostaining across retinal regions may result from several biological and technical factors that researchers should systematically evaluate. Biological explanations include genuine regional expression differences, as demonstrated by the discovery that RPE65 is present in human green/red cones but not in rods or all cone subtypes, suggesting functional specialization . Different photoreceptor populations and densities across retinal regions (such as foveal versus peripheral retina) naturally create variation in RPE65 staining intensity . Age-related changes have been documented in studies using donors of different ages (11 to 85 years), which may affect regional expression patterns . Technical factors that can contribute to variable staining include tissue fixation inconsistencies, where regions with different thickness or vasculature may fix unevenly, affecting epitope preservation . Antigen retrieval efficiency can vary across larger tissue sections, creating artificial gradients in staining intensity . Antibody penetration issues in thicker sections or regions with different tissue density can cause artificial staining patterns . Section quality variations, including tissue folding, tears, or processing artifacts, can create regions of apparently different staining intensity . To address these variables, researchers should implement standardized tissue processing protocols, use multiple antibodies targeting different RPE65 epitopes as cross-validation, include regional positive controls, and systematically document the exact retinal regions being analyzed with reference to anatomical landmarks.

How can specificity be confirmed when working with novel tissue sources?

Confirming RPE65 antibody specificity in novel tissue sources requires a comprehensive validation strategy that extends beyond standard controls. First, perform antibody validation using multiple antibodies targeting different RPE65 epitopes (such as the PETLET and DALEED antibodies) to verify consistent staining patterns, as demonstrated in human retinal tissue studies . Western blot analysis should be conducted on the novel tissue sample to confirm detection of a single band at the expected molecular weight (~63-65 kDa) compared against a positive control (such as RPE homogenate) . Blocking peptide experiments can provide evidence of specificity by pre-incubating the antibody with its immunizing peptide, which should abolish specific staining. RNA confirmation through in situ hybridization or RT-PCR in the novel tissue can verify that RPE65 mRNA is present in regions showing protein immunoreactivity . Knockout/knockdown controls are gold standard validation tools if available for your species; tissues from RPE65-deficient sources should show absence of staining . Co-localization studies with established cell-type markers can help confirm the cellular identity of RPE65-positive cells, as demonstrated in studies differentiating cones from rods and Müller glia . Cross-species validation can provide additional confidence, comparing staining patterns against well-characterized tissues from other species while accounting for known species differences . Progressive dilution testing of the antibody should show decreasing signal intensity without changing the pattern of staining, which helps distinguish specific from non-specific binding.

What controls are essential for RPE65 antibody experiments?

Essential controls for RPE65 antibody experiments span several categories to ensure reliable and interpretable results. Positive tissue controls must include samples with established RPE65 expression (typically RPE tissue) processed identically to experimental samples; these confirm that the staining protocol is functioning properly . Negative tissue controls should include samples known not to express RPE65 or regions within the same tissue lacking expression; studies have shown that rhodopsin-positive rods and glutamine synthetase-positive Müller cells do not express RPE65 and can serve as internal negative controls in retinal sections . Antibody controls should include primary antibody omission controls (using only secondary antibody) to assess non-specific secondary antibody binding, isotype controls (using non-specific IgG from the same species at matching concentration), and absorption controls (pre-incubating the antibody with immunizing peptide) . Dual antibody validation involves using two antibodies targeting different RPE65 epitopes (such as PETLET targeting residues 150-164 and DALEED targeting residues 473-486) to confirm specificity through concordant staining patterns . Multiple application validation provides additional confidence when the same antibody shows consistent results across different techniques (western blot, IHC, ICC) . Concentration gradient controls should demonstrate appropriate signal reduction with antibody dilution without changing localization patterns . For quantitative studies, standard curve controls using recombinant RPE65 protein at known concentrations can enable accurate quantification.

How can antibody cross-reactivity issues be addressed in RPE65 research?

Addressing antibody cross-reactivity issues in RPE65 research requires a systematic approach to identify and eliminate false positive signals. First, epitope sequence analysis should be performed to identify potential cross-reactive proteins; comparing the antibody target sequence (such as PETLET or DALEED epitopes) against protein databases can reveal proteins with similar sequences that might cross-react . Western blot analysis should be conducted to verify that only a single major band appears at the expected molecular weight (~63-65 kDa); the presence of additional bands may indicate cross-reactivity . Sequential immunodepletion can be performed by first immunoprecipitating with the RPE65 antibody, then probing the depleted lysate to confirm absence of the target band while monitoring for persistence of suspected cross-reactive proteins . Knockout/knockdown validation provides definitive evidence when available; tissues from RPE65-deficient models should show complete absence of specific staining while any remaining signal would indicate cross-reactivity . Multiple antibody comparison, using antibodies targeting different RPE65 epitopes (such as PETLET and DALEED), can help distinguish true RPE65 signal (where both antibodies show identical patterns) from cross-reactivity (where patterns differ) . Recombinant expression systems can be used to express RPE65 in cells that normally lack it (such as COS7 cells transfected with human RPE65), providing a controlled system to assess specificity . Species-specific optimization may be necessary, as epitope conservation varies across species (see Table 1 in section 1.4), potentially affecting cross-reactivity profiles . For dual labeling experiments, additional blocking steps may be required to prevent antibody cross-reactivity, particularly when using multiple rabbit-derived antibodies.

How are RPE65 antibodies used in retinal degeneration research?

RPE65 antibodies serve multiple critical functions in retinal degeneration research, allowing investigators to monitor changes in this essential visual cycle protein under pathological conditions. For monitoring disease progression, RPE65 antibodies enable assessment of protein expression changes during degeneration, as RPE65 dysfunction is directly linked to certain forms of retinal degeneration . In therapeutic development, these antibodies are essential for evaluating restoration of RPE65 expression following gene therapy or other interventions targeting the visual cycle . Mechanistic studies benefit from RPE65 antibodies through co-localization experiments with other proteins involved in retinal degeneration pathways, helping elucidate disease mechanisms . Cell-type specific vulnerability can be assessed by examining differential effects on RPE65 expression between RPE cells and cone photoreceptors, particularly important given the recent discovery of RPE65 in human green/red cones . For biomarker development, quantitative analysis of RPE65 levels using calibrated immunoassays may provide prognostic or diagnostic information in certain retinal conditions . Patient sample analysis often includes immunohistochemical evaluation of RPE65 in donor eyes from patients with various retinal degenerations, providing insight into disease-specific changes . In genotype-phenotype correlation studies, RPE65 antibodies allow researchers to assess how different mutations affect protein expression, stability, and localization . Model validation applications include confirming appropriate expression patterns of RPE65 in animal models of retinal degeneration, ensuring they recapitulate human disease features .

What considerations exist for using RPE65 antibodies in developmental studies?

Developmental studies using RPE65 antibodies require specific considerations to accurately track expression patterns throughout retinal maturation. Temporal expression profiling must account for developmental regulation of RPE65, which may show different expression timing between RPE and cone photoreceptors; antibodies with high sensitivity are crucial for detecting potentially low early expression levels . Tissue preparation techniques must be adapted for embryonic and early postnatal tissues, which are typically more fragile and may require specialized fixation protocols to preserve RPE65 epitopes while maintaining tissue integrity . Species-specific developmental timelines must be considered, as the onset of RPE65 expression may vary between species and correlate with different developmental milestones . Co-expression analysis with developmental markers can provide context for RPE65 expression relative to retinal differentiation stages, requiring carefully optimized multiplex immunostaining protocols . Antibody selection should prioritize those validated across developmental stages, as some epitopes might be differentially accessible during development due to protein folding or interaction differences . Quantitative developmental profiling requires consistent processing and imaging parameters across timepoints to allow reliable comparison of expression levels . Three-dimensional analysis may be valuable for understanding spatial relationships during development, necessitating specialized sectioning and imaging techniques compatible with RPE65 antibodies . Control selection must include age-matched tissues, as non-specific binding characteristics may change during development . If studying congenital retinal diseases involving RPE65, developmental analysis using these antibodies can provide insights into early disease mechanisms before clinical manifestation .

How can RPE65 antibodies help distinguish cell types in complex retinal preparations?

RPE65 antibodies have emerged as valuable tools for distinguishing cell types in complex retinal preparations, particularly with the discovery of differential expression patterns across retinal cells. For cone subtype identification, RPE65 antibodies can help distinguish green/red cones from other photoreceptor subtypes, as research has demonstrated specific localization in human green/red cones but not in rods . Multiplex immunolabeling strategies combining RPE65 with established markers (cone arrestin for all cones, rhodopsin for rods, glutamine synthetase for Müller glia) enable comprehensive cell type mapping within retinal sections . Proximity analysis using high-resolution imaging of RPE65-labeled preparations can reveal spatial relationships between the RPE and adjacent photoreceptors, providing insights into visual cycle microanatomy . Quantitative cell type profiling can be achieved by analyzing the proportion of different photoreceptor subtypes based on differential marker expression including RPE65 . For transplantation and stem cell studies, RPE65 antibodies can help verify appropriate differentiation of cells into RPE or specific photoreceptor subtypes . Retinal explant viability assessment may include RPE65 immunostaining to confirm maintenance of normal expression patterns during ex vivo culture . Microdissection guidance can utilize RPE65 expression patterns to help identify specific retinal layers or cell populations for isolation and subsequent analysis . Species comparative studies benefit from RPE65 antibodies to identify potential differences in retinal cell type organization and expression patterns across species, informing appropriate model selection for specific research questions .

What are the implications of RPE65 localization in cones for disease research?

The discovery of RPE65 localization in human green/red cones has significant implications for retinal disease research that researchers should consider when designing studies with RPE65 antibodies. This finding suggests potential cone-specific visual cycle mechanisms that might function independently of or complementary to the classical RPE visual cycle, requiring reinterpretation of disease models focusing solely on RPE dysfunction . Cone-specific vulnerability in RPE65-associated diseases may now be investigated as either primary (due to intrinsic cone RPE65 dysfunction) or secondary (due to RPE dysfunction) phenomena, necessitating cell-type specific analyses using appropriate antibodies . Therapeutic targeting strategies may need refinement to address both RPE and cone-expressed RPE65, potentially requiring different delivery approaches or expression control elements . The species-specificity of this localization pattern must be carefully considered in translational research, as RPE65 expression in cones may differ between humans and common animal models, affecting interpretation of experimental results . Novel disease mechanisms involving cone-specific isomerohydrolase activity may be investigated using RPE65 antibodies to monitor changes in expression or localization under pathological conditions . Genetic variation impact studies can now explore whether different RPE65 variants differently affect RPE versus cone expression, potentially explaining clinical phenotype variations . Cone survival strategies in retinal degeneration may be reassessed considering intrinsic RPE65 expression, using antibodies to track changes during disease progression or following interventions . For biomarker development, differential changes in RPE versus cone RPE65 expression might provide more specific indicators of disease subtypes or progression .

How can RPE65 antibodies be used in combination with other visual cycle markers?

RPE65 antibodies can be strategically combined with other visual cycle markers to create comprehensive experimental designs that elucidate the complex interactions within the retinoid cycle. For pathway mapping experiments, RPE65 can be co-labeled with LRAT (lecithin:retinol acyltransferase), which palmitoylates RPE65 and processes all-trans-retinol into all-trans-retinyl ester, to visualize sequential steps in the visual cycle . Protein interaction studies can combine RPE65 immunoprecipitation with detection of binding partners like LRAT to understand the dynamic protein complexes that facilitate visual chromophore regeneration . Sub-pathway distinction between the classical RPE-dependent visual cycle and potential cone-specific pathways can be investigated by combining RPE65 with cone-specific markers and other visual cycle proteins . Differential regulation studies can simultaneously monitor changes in multiple visual cycle proteins under various conditions, providing insight into coordinated or divergent regulatory mechanisms . Subcellular co-localization analysis pairing RPE65 with markers for different cellular compartments can reveal the precise localization of visual cycle components, particularly important given the dual soluble/membrane-associated forms of RPE65 . Enzymatic activity correlation studies can link immunodetected RPE65 levels with functional assays of isomerohydrolase activity to understand structure-function relationships . Cross-species comparative analyses using antibodies against multiple visual cycle proteins can identify conserved and divergent features between species, informing model selection . For lutein metabolism research, combining RPE65 (which can catalyze lutein isomerization to meso-zeaxanthin) with carotenoid-binding protein antibodies can help elucidate macular pigment metabolism pathways .

What techniques allow for quantification of RPE65 expression levels?

Quantification of RPE65 expression levels can be achieved through several complementary techniques, each with specific methodological considerations for accurate results. Quantitative western blotting requires careful preparation of standard curves using recombinant RPE65 protein, alongside consistent sample loading controls (such as GAPDH or β-actin) and densitometric analysis software . Enzyme-linked immunosorbent assays (ELISA) can be developed using validated RPE65 antibodies as capture and detection reagents, allowing high-throughput quantification with appropriate standard curves and controls . Immunohistochemical quantification involves standardized staining protocols followed by digital image analysis using software that can measure staining intensity in defined regions, requiring consistent imaging parameters and appropriate background correction . Flow cytometry can quantify RPE65 in dissociated cells using fluorophore-conjugated antibodies, though this requires optimization of fixation and permeabilization protocols to preserve the epitope while allowing antibody access . Mass spectrometry-based immunoprecipitation (IP-MS) combines RPE65 antibody-based enrichment with peptide quantification by mass spectrometry, offering high sensitivity and specificity . Multiplex immunoassays can simultaneously quantify RPE65 alongside other proteins of interest, providing contextual information about related pathway components . Single-cell analysis techniques combine immunolabeling with microscopy or cytometry approaches to measure cell-to-cell variation in RPE65 expression, particularly valuable given the differential expression between cell types . For all these methods, careful validation using positive and negative controls, concentration standards, and technical replicates is essential for reliable quantification.

How can RPE65 antibodies contribute to understanding retinoid cycle variations across species?

RPE65 antibodies provide powerful tools for comparative studies of visual cycle mechanisms across species, revealing both conserved functions and evolutionary adaptations. Cross-species epitope validation is an essential first step, as antibody epitopes may show varying degrees of conservation; for example, the PETLET and DALEED epitopes show high but not complete conservation between human, mouse, and bovine RPE65 (see Table 1 in section 1.4) . Cellular localization mapping across species can reveal fundamental differences in visual cycle organization, such as the discovery of RPE65 in human green/red cones, which may not be conserved in all experimental models . Expression level comparative quantification using calibrated immunoassays can identify species differences in RPE65 abundance that might correlate with visual ecology or retinal physiology . Developmental timeline comparison using stage-specific immunostaining can reveal differences in the onset and progression of RPE65 expression during retinal development across species . Cone subtype-specific analysis is particularly important given the differential expression of RPE65 in human cone subtypes, requiring careful co-labeling with species-appropriate cone markers . Protein-protein interaction conservation can be assessed through comparative co-immunoprecipitation studies using RPE65 antibodies across species samples . Diurnal/circadian variation studies may reveal species-specific temporal regulation of RPE65 expression or localization related to activity patterns . For specialized adaptation research, RPE65 antibodies can help investigate visual cycle modifications in species with unusual visual specializations (nocturnal, aquatic, etc.), potentially revealing novel mechanisms . All cross-species comparisons must carefully account for specificity validation in each species and consider evolutionary distances when interpreting results.

What are the latest advances in RPE65 antibody applications for studying macular pigment metabolism?

Recent advances have expanded the application of RPE65 antibodies to the study of macular pigment metabolism, building on the discovery that RPE65 can catalyze the isomerization of lutein to meso-zeaxanthin, an eye-specific carotenoid . Co-localization studies are now mapping the spatial relationship between RPE65 expression and macular pigment distribution using immunohistochemistry combined with carotenoid imaging techniques . Pathway reconstruction experiments utilize RPE65 antibodies alongside other carotenoid-processing enzymes to elucidate the complete metabolic pathway for meso-zeaxanthin formation . Age-related changes in the lutein isomerase function of RPE65 can be investigated through comparative immunohistochemistry studies in donor eyes of various ages (11-85 years), correlating with macular pigment measurements . Structure-function studies are examining how specific domains of RPE65 (identified using epitope-specific antibodies like PETLET and DALEED) contribute to its dual functions in retinoid isomerization and carotenoid metabolism . Cell-type specific contributions to macular pigment processing are being assessed through differential analysis of RPE65 in RPE versus cone photoreceptors, providing insight into compartmentalized carotenoid metabolism . Disease-related alterations in RPE65-mediated carotenoid processing are being evaluated in macular conditions associated with pigment abnormalities, using immunohistochemistry to detect changes in expression or localization . Quantitative correlation analyses are relating RPE65 expression levels to macular pigment optical density measurements in corresponding retinal regions . For intervention studies, RPE65 antibodies are helping track changes in the carotenoid-processing machinery following supplementation or therapeutic interventions targeting macular pigment enhancement .